Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8(+) T and NK cell function

Pegylated interferon-alpha (PegIFNα) therapy has limited effectiveness in hepatitis B e-antigen (HBeAg)-positive chronic hepatitis B (CHB) patients. However, the mechanism underlying this failure is poorly understood. We aimed to investigate the influence of bile acids (BAs), especially taurocholic...

Descripción completa

Detalles Bibliográficos
Autores principales: Xun, Zhen, Lin, Jinpiao, Yu, Qingqing, Liu, Can, Huang, Jinlan, Shang, Hongyan, Guo, Jianhui, Ye, Yuchen, Wu, Wennan, Zeng, Yongbin, Wu, Songhang, Xu, Siyi, Chen, Tianbin, Chen, Jing, Ou, Qishui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027018/
https://www.ncbi.nlm.nih.gov/pubmed/33432062
http://dx.doi.org/10.1038/s41423-020-00601-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027018/
https://www.ncbi.nlm.nih.gov/pubmed/33432062
http://dx.doi.org/10.1038/s41423-020-00601-8

Ejemplares similares